Cargando…

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function

Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD). Although hyperuricemia is a risk factor for CKD progression, the causal role of uric acid remains controversial in patients with CKD and asymp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Hee Jung, Oh, Jieun, Shin, Dong Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6576756/ https://www.ncbi.nlm.nih.gov/pubmed/31206563 http://dx.doi.org/10.1371/journal.pone.0218510

Ejemplares similares

Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
por: Eleftheriadis, Theodoros, et al.
Publicado: (2017)

To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
por: Shin, Dong Ho
Publicado: (2019)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
por: Zhang, Lin, et al.
Publicado: (2022)

Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia
por: Ueno, Naohiko
Publicado: (2017)

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
por: Sharma, Gaurav, et al.
Publicado: (2021)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
por: Lee, Tao Han, et al.
Publicado: (2021)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
por: Sapankaew, Tunlanut, et al.
Publicado: (2022)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey
por: Cha, Ran-hui, et al.
Publicado: (2019)

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
por: Waheed, Yousuf, et al.
Publicado: (2021)

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
por: Bove, Marilisa, et al.
Publicado: (2017)

Kidney Stones and Risk of Osteoporotic Fracture in Chronic Kidney Disease
por: Han, Seung Gyu, et al.
Publicado: (2019)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
por: Honda, Masataka, et al.
Publicado: (2021)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
por: Chung, Ting-Ting, et al.
Publicado: (2019)

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency
por: Wu, Mian, et al.
Publicado: (2021)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review
por: Ramirez, Maria Erika G., et al.
Publicado: (2017)

The grey zone of Hyperuricemia in chronic kidney disease
por: Dousdampanis, Periklis
Publicado: (2017)

Hyperuricemia and chronic kidney disease: to treat or not to treat
por: Piani, Federica, et al.
Publicado: (2021)

Vegan Diet Is Associated with a Lower Risk of Chronic Kidney Disease in Patients with Hyperuricemia
por: Wu, Chia-Lin, et al.
Publicado: (2023)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study
por: Kielstein, Jan T, et al.
Publicado: (2019)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia
por: Cabău, Georgiana, et al.
Publicado: (2019)

The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia
por: Wu, Liting, et al.
Publicado: (2021)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Urate Transporters in the Kidney: What Clinicians Need to Know
por: Chung, Sungjin, et al.
Publicado: (2021)

Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis
por: Li, Shu, et al.
Publicado: (2016)

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
por: Kanji, Tahir, et al.
Publicado: (2015)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Decreased extra-renal urate excretion is a common cause of hyperuricemia
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lc47rpfhh323bcu8cbsic5rp76